Summary

The U.S. Food and Drug Administration's decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug had prolonged the lives of a third of the participants in a clinical trial. "It was devastating news," said Dr. Trisha Wise-Draper, a dermatologist at the University of Cincinnati who had patients enrolled in the trial.

AI summaries can be wrong sometimes—always verify important details using the source article.